Availability of FLT3 inhibitors: how do we use them?

被引：33
作者：
Perl, Alexander E. [1 ]
机构：
[1] Univ Penn, Leukemia Program, Abramson Canc Ctr, Philadelphia, PA 19104 USA
来源：
BLOOD | 2019年 / 134卷 / 09期
关键词：
ACUTE MYELOID-LEUKEMIA; INTERNAL TANDEM DUPLICATION; CELL TRANSPLANTATION; PHASE-I; SORAFENIB; MUTATIONS; GILTERITINIB; CHEMOTHERAPY; DIFFERENTIATION; MULTICENTER;
D O I：
10.1182/blood.2019876821
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The natural history of FLT3-mutated AML is changing after the approval of midostaurin for frontline therapy and gilteritinib for relapsed or refractory patients. Recently reported, positive randomized trials of the drugs gilteritinib, quizartinib, and sorafenib predict even wider use of FLT3 inhibitors going forward. FLT3 inhibitors now emerge as an important, if not indispensable, part of therapy for a large subset of high-risk patients.
引用
收藏
页码：741 / 745
页数：5
相关论文
共 46 条
  • [31] Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation
    Ravandi, Farhad
    Alattar, Mona Lisa
    Grunwald, Michael R.
    Rudek, Michelle A.
    Rajkhowa, Trivikram
    Richie, Mary Ann
    Pierce, Sherry
    Daver, Naval
    Garcia-Manero, Guillermo
    Faderl, Stefan
    Nazha, Aziz
    Konopleva, Marina
    Borthakur, Gautam
    Burger, Jan
    Kadia, Tapan
    Dellasala, Sara
    Andreeff, Michael
    Cortes, Jorge
    Kantarjian, Hagop
    Levis, Mark
    [J]. BLOOD, 2013, 121 (23) : 4655 - 4662
  • [32] Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
    Rollig, Christoph
    Serve, Hubert
    Huettmann, Andreas
    Noppeney, Richard
    Mueller-Tidow, Carsten
    Krug, Utz
    Baldus, Claudia D.
    Brandts, Christian H.
    Kunzmann, Volker
    Einsele, Hermann
    Kraemer, Alwin
    Schaefer-Eckart, Kerstin
    Neubauer, Andreas
    Burchert, Andreas
    Giagounidis, Aristoteles
    Krause, Stefan W.
    Mackensen, Andreas
    Aulitzky, Walter
    Herbst, Regina
    Haenel, Mathias
    Kiani, Alexander
    Frickhofen, Norbert
    Kullmer, Johannes
    Kaiser, Ufrich
    Link, Hartmut
    Geer, Thomas
    Reiche, Albert
    Junghanss, Christian
    Repp, Roland
    Heits, Frank
    Duerk, Heinz
    Hase, Jana
    Klut, Ina-Maria
    Illmer, Thomas
    Bornhaeuser, Martin
    Schaich, Markus
    Parmentier, Stefani
    Goerner, Martin
    Thiede, Christian
    von Bonin, Malte
    Schetelig, Johannes
    Kramer, Michael
    Berdel, Welfgang E.
    Ehninger, Gerhard
    [J]. LANCET ONCOLOGY, 2015, 16 (16) : 1691 - 1699
  • [33] Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia
    Schlenk, Richard F.
    Doehner, Konstanze
    Krauter, Juergen
    Froehling, Stefan
    Corbacioglu, Andrea
    Bullinger, Lars
    Habdank, Marianne
    Spaeth, Daniela
    Morgan, Michael
    Benner, Axel
    Schlegelberger, Brigitte
    Heil, Gerhard
    Ganser, Arnold
    Doehner, Hartmut
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (18) : 1909 - 1918
  • [34] Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD
    Schlenk, Richard F.
    Weber, Daniela
    Fiedler, Walter
    Salih, Helmut R.
    Wulf, Gerald
    Salwender, Hans
    Schroeder, Thomas
    Kindler, Thomas
    Luebber, Michael
    Wolf, Dominik
    Westermann, Joerg
    Kraemer, Doris
    Goetze, Katharina S.
    Horst, Heinz-August
    Krauter, Juergen
    Girschikofsky, Michael
    Ringhoffer, Mark
    Suedhoff, Thomas
    Held, Gerhard
    Derigs, Hans-Guenter
    Schroers, Roland
    Greil, Richard
    Griesshammer, Martin
    Lange, Elisabeth
    Burchardt, Alexander
    Martens, Uwe
    Hertenstein, Bernd
    Marretta, Lore
    Heuser, Michael
    Thol, Felicitas
    Gaidzik, Verena, I
    Herr, Wolfgang
    Krzykalla, Julia
    Benner, Axel
    Doehner, Konstanze
    Ganser, Arnold
    Paschka, Peter
    Doehner, Hartmut
    [J]. BLOOD, 2019, 133 (08) : 840 - 851
  • [35] Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation
    Schlenk, Richard F.
    Kayser, Sabine
    Bullinger, Lars
    Kobbe, Guido
    Casper, Jochen
    Ringhoffer, Mark
    Held, Gerhard
    Brossart, Peter
    Luebbert, Michael
    Salih, Helmut R.
    Kindler, Thomas
    Horst, Heinz A.
    Wulf, Gerald
    Nachbaur, David
    Goetze, Katharina
    Lamparter, Alexander
    Paschka, Peter
    Gaidzik, Verena I.
    Teleanu, Veronica
    Spaeth, Daniela
    Benner, Axel
    Krauter, Juergen
    Ganser, Arnold
    Doehner, Hartmut
    Doehner, Konstanze
    [J]. BLOOD, 2014, 124 (23) : 3441 - 3449
  • [36] Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia:: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease
    Schnittger, S
    Schoch, C
    Dugas, M
    Kern, W
    Staib, P
    Wuchter, C
    Löffler, H
    Sauerland, CM
    Serve, H
    Büchner, T
    Haferlach, T
    Hiddemann, W
    [J]. BLOOD, 2002, 100 (01) : 59 - 66
  • [37] Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial
    Serve, Hubert
    Krug, Utz
    Wagner, Ruth
    Sauerland, M. Cristina
    Heinecke, Achim
    Brunnberg, Uta
    Schaich, Markus
    Ottmann, Oliver
    Duyster, Justus
    Wandt, Hannes
    Fischer, Thomas
    Giagounidis, Aristoteles
    Neubauer, Andreas
    Reichle, Albrecht
    Aulitzky, Walter
    Noppeney, Richard
    Blau, Igor
    Kunzmann, Volker
    Stuhlmann, Reingard
    Kraemer, Alwin
    Kreuzer, Karl-Anton
    Brandts, Christian
    Steffen, Bjoern
    Thiede, Christian
    Mueller-Tidow, Carsten
    Ehninger, Gerhard
    Berdel, Wolfgang E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (25) : 3110 - +
  • [38] Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITDAML
    Sexauer, Amy
    Perl, Alexander
    Yang, Xiaochuan
    Borowitz, Michael
    Gocke, Christopher
    Rajkhowa, Trivikram
    Thiede, Christian
    Frattini, Mark
    Nybakken, Grant E.
    Pratz, Keith
    Karp, Judith
    Smith, B. Douglas
    Levis, Mark
    [J]. BLOOD, 2012, 120 (20) : 4205 - 4214
  • [39] Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
    Smith, Catherine C.
    Wang, Qi
    Chin, Chen-Shan
    Salerno, Sara
    Damon, Lauren E.
    Levis, Mark J.
    Perl, Alexander E.
    Travers, Kevin J.
    Wang, Susana
    Hunt, Jeremy P.
    Zarrinkar, Patrick P.
    Schadt, Eric E.
    Kasarskis, Andrew
    Kuriyan, John
    Shah, Neil P.
    [J]. NATURE, 2012, 485 (7397) : 260 - U153
  • [40] Crenolanib is a selective type I pan-FLT3 inhibitor
    Smith, Catherine Choy
    Lasater, Elisabeth A.
    Lin, Kimberly C.
    Wang, Qi
    McCreery, Melissa Quino
    Stewart, Whitney K.
    Damon, Lauren E.
    Perl, Alexander E.
    Jeschke, Grace R.
    Sugita, Mayumi
    Carroll, Martin
    Kogan, Scott C.
    Kuriyan, John
    Shah, Neil P.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2014, 111 (14) : 5319 - 5324
12345